Acadia Pharmaceuticals | ACAD - Market Capitalization


Acadia Pharmaceuticals reported $3.92B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
ALKERMES USD 5.88B 1.26B Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Cara Therapeutics USD 366M 338M Sep/2025
Corcept Therapeutics USD 4.32B 654M Mar/2026
Cytokinetics USD 8.19B 420M Mar/2026
Eisai JPY 1.42T 110.62B Mar/2026
Eli Lilly USD 869.02B 146.97B Mar/2026
Incyte USD 18.73B 660M Mar/2026
J&J USD 579.15B 78.91B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
Pfizer USD 153.81B 12.24B Mar/2026
PTC Therapeutics USD 5.64B 460M Mar/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024
Vertex Pharmaceuticals USD 113.58B 1.44B Mar/2026